GPR37 processing in neurodegeneration: a potential marker for Parkinson’s Disease progression rate. npj Parkinson's Disease , 2024; 10 (1) DOI: 10.1038/s41531-024-00788-x Cite This Page : ...
Yasir Gallero-Salas discusses quantifying alpha-synuclein spread and dopaminergic neuron loss in a model of Parkinson’s using ...
Environmental factors like prolonged stress, chronic inflammation and toxic exposure could play a key role in triggering ...
Exidavnemab is being developed as a potential disease-modifying treatment, aiming to halt or slow the progression of ...
Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...
BioArctic AB (publ), a Swedish research-based biopharma company, announced that the first patient has been dosed with exidavnemab in the EXIST phase 2a study, in Parkinson’s disease patients.
When Denver artist Tim McKay was diagnosed with Parkinson’s disease last year, he made a quick decision: He would document ...
Wearable devices once seemed futuristic for Parkinson’s disease. Today, tools like activity trackers, tremor gloves, and ...
The company is hoping to show GT-02287 can slow Parkinson's progression by restoring function of GCase, an enzyme encoded by ...
SOUTH SAN FRANCISCO, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: DNLI) today announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the investigational drug ...